NASDAQ:AXGN - AxoGen Stock Price, Forecast & News

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen, Inc (NASDAQ:AXGN) announced its earnings results on Monday, October, 29th. The medical equipment provider reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The medical equipment provider had revenue of $22.66 million for the quarter, compared to the consensus estimate of $22.52 million. AxoGen had a negative net margin of 26.79% and a negative return on equity of 17.82%. The business's quarterly revenue was up 41.2% on a year-over-year basis. During the same period last year, the company posted ($0.04) EPS. View AxoGen's Earnings History.

AxoGen is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for AxoGen.

AxoGen will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AxoGen issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $106.6 million, compared to the consensus revenue estimate of $107.76 million.

5 brokers have issued 12 month price objectives for AxoGen's stock. Their forecasts range from $21.00 to $30.00. On average, they anticipate AxoGen's stock price to reach $25.00 in the next year. This suggests a possible upside of 78.3% from the stock's current price. View Analyst Price Targets for AxoGen.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.

News articles about AXGN stock have trended somewhat positive on Monday, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AxoGen earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for AxoGen.

AxoGen saw a drop in short interest in January. As of January 31st, there was short interest totalling 1,660,000 shares, a drop of 18.6% from the January 15th total of 2,040,000 shares. Based on an average trading volume of 355,000 shares, the days-to-cover ratio is currently 4.7 days. Approximately 4.7% of the shares of the stock are sold short. View AxoGen's Current Options Chain.

Some companies that are related to AxoGen include InMode (INMD), Natus Medical (NTUS), TransMedics Group (TMDX), Cutera (CUTR), Semler Scientific (SMLR), Zynex (ZYXI), Viewray (VRAY), BioLife Solutions (BLFS), Stereotaxis (STXS), Rockwell Medical (RMTI), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), BioSig Technologies (BSGM) and Second Sight Medical Products (EYES).

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Advanced Micro Devices (AMD), Exelixis (EXEL), Xilinx (XLNX), Micron Technology (MU), Bank of America (BAC), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Amarin (AMRN) and NVIDIA (NVDA).

AxoGen's stock is owned by a number of of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (15.15%), Baillie Gifford & Co. (2.61%), State Street Corp (2.55%), William Blair Investment Management LLC (2.34%), Bank of New York Mellon Corp (2.22%) and Bank of America Corp DE (2.21%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Jamie Mark Grooms, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

AXGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Bank of New York Mellon Corp, Renaissance Technologies LLC, Peregrine Capital Management LLC, Goldman Sachs Group Inc., Penn Capital Management Co. Inc., Perkins Capital Management Inc. and BerganKDV Wealth Management LLC. Company insiders that have sold AxoGen company stock in the last year include David K Hansen and Michael Patrick Donovan. View Insider Buying and Selling for AxoGen.

AXGN stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, William Blair Investment Management LLC, Point72 Asset Management L.P., Bank of America Corp DE, Bank of Montreal Can, Jacobs Levy Equity Management Inc., Granite Investment Partners LLC and Baillie Gifford & Co.. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej and Quentin S Blackford. View Insider Buying and Selling for AxoGen.

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXGN stock can currently be purchased for approximately $14.02.

AxoGen has a market capitalization of $553.37 million and generates $83.94 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. View Additional Information About AxoGen.

The official website for AxoGen is http://www.axogeninc.com/.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]